Evidence map›Paper›PMID 32760917›Full record

ArticleJACC. Basic to translational science2020

Neprilysin in HFrEF: Differential Regulation of Tissue Versus Circulating Neprilysin.

Horng H Chen, John C Burnett

Open access · goldAbstract readEditorial
In one paragraph

Article in JACC. Basic to translational science, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
0.1field-weighted citation impact, top 55% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 1 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors at 1 institution in 1 country.

Horng H ChenDepartment of Cardiovascular Diseases, Cardiorenal Research Laboratory, Mayo Clinic, Rochester, Minnesota.
John C BurnettDepartment of Cardiovascular Diseases, Cardiorenal Research Laboratory, Mayo Clinic, Rochester, Minnesota.
Mayo Clinic · US

Funding

Human Cardiorenal SyndromeR01HL084155 · NHLBI · MAYO CLINIC ROCHESTER · PI HORNG H CHEN · 2009 to 2026
$5.5M
Preclinical Diastolic Dysfunction in Type 2 DiabetesR01HL136440 · NHLBI · MAYO CLINIC ROCHESTER · PI CHEN, HORNG H · 2018 to 2021
$2.8M
Novel Peptide Therapeutics for Cardiorenal Protection in Heart FailureR01HL134668 · NHLBI · MAYO CLINIC ROCHESTER · PI BURNETT, JOHN C · 2017 to 2020
$1.6M
NHLBI NIH HHS R01 HL084155NHLBI NIH HHS R01 HL134668NHLBI NIH HHS R01 HL136440
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

heart failurenatriuretic peptidesneprilysin

Identifiers

PMID32760917
PMCPMC7393426
OpenAlexW3044490682

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.